Medicare provides coverage and reimbursement frameworks for Barostim therapy when administered to patients who meet specific clinical criteria for heart failure with reduced ejection fraction. Government health insurance programs and local Medicare Administrative Contractors have established structured billing codes and institutional payment classifications (such as inpatient MS-DRG and outpatient APC guidelines) that cover the costs of the device and the surgical implantation procedure. This robust reimbursement landscape significantly reduces out-of-pocket financial hurdles for eligible Medicare beneficiaries seeking advanced neuromodulation treatment.